PTEN and neoplasm: Aside from the known brain glioma tumor suppressors, CDKN2A, NF1, and PTEN, we found SPRED1 is deleted (heterozygous or homozygous) in 12% of LGGs and 27% of GBMs; and TCF12 deletions and/or truncating mutations are present in 15% of LGGs and 23% of GBMs—indeed SPRED1 and TCF12 are mostly co-deleted (p < 0.001, Fisher’s exact test) likely as part of a 15q deletion [76].